Cargando…

A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas

Background and Objective: Investigating the use of radiofrequency myolysis (RFM) for the treatment of fibroids through less invasive access by combining transvaginal ultrasound, hysteroscopy and laparoscopy. Materials and Methods: Fifty-four premenopausal women with 106 symptomatic uterine myomas. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Fasciani, Alessandro, Turtulici, Giovanni, Siri, Giacomo, Ferrero, Simone, Sirito, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7143923/
https://www.ncbi.nlm.nih.gov/pubmed/32178351
http://dx.doi.org/10.3390/medicina56030122
_version_ 1783519727271804928
author Fasciani, Alessandro
Turtulici, Giovanni
Siri, Giacomo
Ferrero, Simone
Sirito, Rodolfo
author_facet Fasciani, Alessandro
Turtulici, Giovanni
Siri, Giacomo
Ferrero, Simone
Sirito, Rodolfo
author_sort Fasciani, Alessandro
collection PubMed
description Background and Objective: Investigating the use of radiofrequency myolysis (RFM) for the treatment of fibroids through less invasive access by combining transvaginal ultrasound, hysteroscopy and laparoscopy. Materials and Methods: Fifty-four premenopausal women with 106 symptomatic uterine myomas. Patients underwent RFM in three ways: Vaginal Ultrasound-guided RFM (VU-RFM), Laparoscopic RFM (L-RFM) and Hysteroscopic-RFM (H-RFM). The mean patient age was 43 years; 52 symptomatic uterine myomas were subserosal, 44 intramural and 10 submucosal. The outcomes evaluated at 1 and 12 months after RFM were myoma size (volume-diameter), “Uterine Fibroid Symptom and Quality of Life (UFS-QOL)” questionnaire and a 10-point Visual Analogue Scale (VAS). The therapy was completed with a single ablation in all patients, no complication was registered. The average number of fibroids treated per intervention was two with the use of different accesses: 64/106 VU-RFMs (60.4%), 32/106 L-RFMs (30.2%) and 10/106 H-RFMs (9.4%). Results: Volume and diameter of fibroids were significantly reduced by, respectively, 51.3% and 20.1% in the first 30 days post-intervention (p < 0.001) up to a maximum of 73.5% and 37.1% after the second follow-up visit at 12 months (p < 0.001). A similar trend was shown in terms of disability with a progressive and significant reduction of symptoms (menorrhagia, dysmenorrhea, dyspareunia and pollakiuria) demonstrated by percentage variation of UFS-QOL Symptom Severity and VAS scores to −74.3% and −45.3% as well as −84.9% and −74.3%, respectively, at 1 and 12 months after RFM (p < 0.001). An overall improvement in the quality of life was also demonstrated by a significant increase in the UFS-QOL total score of +38.2% in the first 30 days post-intervention up to +44.9% after the second follow-up visit at 12 months (p < 0.001). The overall average surgery time of the RFM for each patient was 48 minutes, and the time to treat each fibroid by Vaginal Ultrasound-guided RFM (23 min) was found to be significantly less than those of laparoscopy or hysteroscopy (respectively 35 and 34 min) (p < 0.05). An electromagnetic virtual needle tracking system (VNTS) was successfully tested during the RFM procedures, and real-time contrast-enhanced ultrasound (CEUS) has proven to be effective in determining the duration of myolysis through the identification of eventual residual areas of enhancement within the fibroids. Conclusion: Radiofrequency can be considered a minimally invasive and safe procedure for the treatment of uterine myomas through the customization and possible combination of transvaginal, laparoscopic or hysteroscopic accesses. The standardization of the ablation technique with pre-intervention biopsy and new technologies such as VNTS and CEUS spares healthy uterine tissue and may change the future management of symptomatic uterine fibroids.
format Online
Article
Text
id pubmed-7143923
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71439232020-04-14 A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas Fasciani, Alessandro Turtulici, Giovanni Siri, Giacomo Ferrero, Simone Sirito, Rodolfo Medicina (Kaunas) Article Background and Objective: Investigating the use of radiofrequency myolysis (RFM) for the treatment of fibroids through less invasive access by combining transvaginal ultrasound, hysteroscopy and laparoscopy. Materials and Methods: Fifty-four premenopausal women with 106 symptomatic uterine myomas. Patients underwent RFM in three ways: Vaginal Ultrasound-guided RFM (VU-RFM), Laparoscopic RFM (L-RFM) and Hysteroscopic-RFM (H-RFM). The mean patient age was 43 years; 52 symptomatic uterine myomas were subserosal, 44 intramural and 10 submucosal. The outcomes evaluated at 1 and 12 months after RFM were myoma size (volume-diameter), “Uterine Fibroid Symptom and Quality of Life (UFS-QOL)” questionnaire and a 10-point Visual Analogue Scale (VAS). The therapy was completed with a single ablation in all patients, no complication was registered. The average number of fibroids treated per intervention was two with the use of different accesses: 64/106 VU-RFMs (60.4%), 32/106 L-RFMs (30.2%) and 10/106 H-RFMs (9.4%). Results: Volume and diameter of fibroids were significantly reduced by, respectively, 51.3% and 20.1% in the first 30 days post-intervention (p < 0.001) up to a maximum of 73.5% and 37.1% after the second follow-up visit at 12 months (p < 0.001). A similar trend was shown in terms of disability with a progressive and significant reduction of symptoms (menorrhagia, dysmenorrhea, dyspareunia and pollakiuria) demonstrated by percentage variation of UFS-QOL Symptom Severity and VAS scores to −74.3% and −45.3% as well as −84.9% and −74.3%, respectively, at 1 and 12 months after RFM (p < 0.001). An overall improvement in the quality of life was also demonstrated by a significant increase in the UFS-QOL total score of +38.2% in the first 30 days post-intervention up to +44.9% after the second follow-up visit at 12 months (p < 0.001). The overall average surgery time of the RFM for each patient was 48 minutes, and the time to treat each fibroid by Vaginal Ultrasound-guided RFM (23 min) was found to be significantly less than those of laparoscopy or hysteroscopy (respectively 35 and 34 min) (p < 0.05). An electromagnetic virtual needle tracking system (VNTS) was successfully tested during the RFM procedures, and real-time contrast-enhanced ultrasound (CEUS) has proven to be effective in determining the duration of myolysis through the identification of eventual residual areas of enhancement within the fibroids. Conclusion: Radiofrequency can be considered a minimally invasive and safe procedure for the treatment of uterine myomas through the customization and possible combination of transvaginal, laparoscopic or hysteroscopic accesses. The standardization of the ablation technique with pre-intervention biopsy and new technologies such as VNTS and CEUS spares healthy uterine tissue and may change the future management of symptomatic uterine fibroids. MDPI 2020-03-12 /pmc/articles/PMC7143923/ /pubmed/32178351 http://dx.doi.org/10.3390/medicina56030122 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fasciani, Alessandro
Turtulici, Giovanni
Siri, Giacomo
Ferrero, Simone
Sirito, Rodolfo
A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas
title A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas
title_full A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas
title_fullStr A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas
title_full_unstemmed A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas
title_short A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas
title_sort prospective intervention trial on tailored radiofrequency ablation of uterine myomas
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7143923/
https://www.ncbi.nlm.nih.gov/pubmed/32178351
http://dx.doi.org/10.3390/medicina56030122
work_keys_str_mv AT fascianialessandro aprospectiveinterventiontrialontailoredradiofrequencyablationofuterinemyomas
AT turtulicigiovanni aprospectiveinterventiontrialontailoredradiofrequencyablationofuterinemyomas
AT sirigiacomo aprospectiveinterventiontrialontailoredradiofrequencyablationofuterinemyomas
AT ferrerosimone aprospectiveinterventiontrialontailoredradiofrequencyablationofuterinemyomas
AT siritorodolfo aprospectiveinterventiontrialontailoredradiofrequencyablationofuterinemyomas
AT fascianialessandro prospectiveinterventiontrialontailoredradiofrequencyablationofuterinemyomas
AT turtulicigiovanni prospectiveinterventiontrialontailoredradiofrequencyablationofuterinemyomas
AT sirigiacomo prospectiveinterventiontrialontailoredradiofrequencyablationofuterinemyomas
AT ferrerosimone prospectiveinterventiontrialontailoredradiofrequencyablationofuterinemyomas
AT siritorodolfo prospectiveinterventiontrialontailoredradiofrequencyablationofuterinemyomas